基因重组人白细胞介素-11治疗恶性肿瘤化疗所致血小板减少症的临床探讨

Clinical study of interleukin-11(IL-11) in the treatment of thrombocytopenia caused by the chemotherapy of malignant tumor

目的观察基因重组人白细胞介素-11（rhIL-11）治疗恶性肿瘤化疗所致血小板减少症的临床疗效及不良反应。方法本组51例患者随机分为治疗组（27例）和对照组（24例）。治疗组病例化疗后外周血血小板计数≤50×10^9／L时，给予rhIL-11 1．5mg皮下注射，1／d，连续用药5—14d，平均9．2d；当外周血血小板升至≥100×10^9／L时停用rhIL-11观察血像。对照组病例仅以输注血小板及对症治疗为主。结果治疗组患者应用rhIL-11前后自身比较血小板计数最低值显著升高，差异有显著性（P〈0．01）；治疗组患者化疗后应用rhIL-11血小板计数最低值较对照组化疗后的最低值显著升高，差异也有显著性（P〈0．01）；治疗组应用白介素-11后血小板计数低于5．0×10^9／L的天数比对照组明显缩短，两者比较差异也有显著性（P〈0．01）。共治疗27例恶性肿瘤化疗所致的血小板减少症，显效9例（33．3％），有效18例（66．7％）。结论在恶性肿瘤化疗所致的血小板减少症的治疗中，rhIL-11的升血小板作用显著、安全、经济实用。

Objective To study the clinical efficacy and side effect of IL-11 in the treatment of thrombocytopenia caused by the chemotherapy of malignant tumor. Method Fifty-one patients with malignant tumors were divided randomly into the treated group （n = 27 ） and the control group（ n = 24）. The treatment with IL-11 （ 1.5mg, IH, once per day） was given once their platelet counts were lower than 50×10^9/L during the chemotherapy. The duration of treatment was 5-14 days, with average of 9.2 days until the platelet count increased to 100 ×10^9/L. The control group was only given intravenous infusion of platelets when necessary. Results The lowest piateiet count increased significantly in the treated group after giving IL-11, which was significantly different from that in the control group. The duration of platelet count lower than 50 ×10^9/L in the treated group was also significantly shorter than that in the control group. Of the 27 cases in the treated group,9 had complete response（33.3% ） and 18 had partial response（66.7% ）. Conclusion IL-11 is an effective, safe and economical way for the treatment of thrombocytopenia caused by the chemotherapy of malignant tumor.